Dutch Startup Affix Labs Raises €1M to Scale Neurotoxic-Free Insect Repellent Amidst Tightening EU Rules

NIJMEGEN, Netherlands – April 23, 2026 – Dutch Green Chemtech startup Affix Labs has successfully closed a €1 million funding round to accelerate the European expansion of its innovative insect repellent technology. The investment, led by impact-focused family office VP Capital and regional development agency Oost NL, provides a significant boost for the company's flagship product, Repeltec, at a critical moment when European regulations are systematically phasing out traditional chemical pesticides.

Affix Labs is poised to disrupt a multi-billion dollar market by offering a solution that is both highly effective and environmentally conscious. Its patented technology creates a long-lasting, neurotoxic-free surface barrier that repels insects for up to 12 weeks, providing a compelling alternative to products reliant on compounds facing increasing regulatory scrutiny and public concern.

A Solution Timed for a Regulatory Shift

The funding arrives as a regulatory wave sweeps across the European Union, fundamentally reshaping the pest control landscape. Driven by the EU's ambitious 'Farm to Fork' strategy, which aims to cut the use of chemical pesticides by 50% by 2030, national governments are implementing stricter controls. Germany has been a forerunner, with its 2025 'self-service ban' set to remove a broad category of neurotoxic insecticides from open retail shelves, a move other member states are beginning to emulate.

This regulatory pressure creates a significant market vacuum for safe, compliant, and effective alternatives. Affix Labs' Repeltec is strategically positioned to fill this gap. The product's core technology has already navigated the EU's rigorous Biocidal Products Regulation (BPR) process, securing active substance authorizations in key markets including Germany, France, Austria, and Norway. This pre-emptive compliance gives the company a substantial head start over competitors who may need to reformulate or withdraw products.

The market dynamics strongly favor this shift. The European pest control market, valued at over $6.8 billion in 2024, is projected to grow steadily, with the sustainable solutions segment experiencing the most rapid expansion. Climate change is expanding the habitats of disease-carrying insects like mosquitoes, while increased urbanization brings humans into closer contact with pests, driving consumer demand for protection that doesn't compromise on health or environmental safety.

The Science of Safer Repellency

At the heart of Affix Labs' innovation is a patented formulation method that overcomes a long-standing challenge in chemical engineering: dissolving oily, water-insoluble active ingredients into a stable, water-based system. This breakthrough allows the company to use Picaridin—an active ingredient inspired by natural pepper extracts and widely regarded for its safety and efficacy—in a novel surface coating.

When applied, the water-based liquid dries into a transparent, odorless, and durable layer. A controlled-release mechanism embedded within this layer then slowly emits the active ingredient over an extended period, creating a protective 'halo' that repels insects without killing them. This controlled release is the key to Repeltec's claimed 12-week efficacy, a duration that far exceeds most consumer-grade repellents and reduces the need for frequent reapplication.

By focusing on repellency rather than lethality, the technology avoids the use of neurotoxic compounds, such as pyrethroids and organophosphates, which are common in traditional insecticides and are the primary targets of the new EU regulations. Furthermore, the company emphasizes consumer safety, noting that its formulations are dermatologically tested and certified as non-irritant upon accidental skin contact. This positions Repeltec as a unique offering that bridges the performance gap between powerful-but-harsh chemical insecticides and gentle-but-often-short-lived natural alternatives.

Strategic Capital for European Conquest

The €1 million in new capital, provided by investors with a clear focus on sustainability and innovation, will fuel a multi-faceted expansion strategy. VP Capital's 'impact-first' investment philosophy aligns perfectly with Affix Labs' mission to reduce global pesticide dependency. Similarly, Oost NL's mandate to foster economic growth and sustainable technology in the East Netherlands region underscores the local and national significance of the startup's work.

The funds are earmarked for an aggressive European rollout. Building on its existing authorizations, Affix Labs will concentrate on strengthening its distribution channels in Germany, Austria, France, and Norway. The next phase of expansion will target the United Kingdom and Poland, two major markets with growing demand for modern pest control solutions. This strategic geographic push aims to establish Repeltec as the leading sustainable alternative across the continent.

Beyond the Bottle: A 'Powered By' Partnership Model

Beyond its own consumer product lines, Affix Labs is pursuing an ambitious and scalable B2B white-label strategy under the banner 'Powered by Affix Labs'. This model invites other companies to integrate the patented repellent technology into their own products, dramatically expanding its reach and application.

This approach opens up vast commercial possibilities across multiple industries. Fast-Moving Consumer Goods (FMCG) manufacturers can create new lines of insect-repellent household cleaners, laundry additives, or outdoor gear. For the hospitality industry, from global hotel chains to local restaurants, the ability to treat rooms, textiles, and outdoor patios with a long-lasting, non-toxic repellent offers a powerful way to enhance guest comfort and safety while bolstering their own sustainability credentials.

Professional pest control operators also stand to benefit significantly. By incorporating Repeltec into their service offerings, they can provide clients with a greener, regulatory-compliant solution that aligns with Integrated Pest Management (IPM) principles. The 12-week efficacy could reduce the frequency of service calls, improving operational efficiency and offering a distinct competitive advantage in a market rapidly moving away from chemical-heavy treatments. This partnership model allows Affix Labs to focus on its core competency—research and development—while leveraging the established market presence and distribution networks of major industry players to scale its impact globally.